Dibenzocycloheptan-dioxolan derivatives and their preparation method

ABSTRACT

The invention relates to dibenzo-cycloheptan-dioxolan derivatives having antispastic activity and the method of preparing them.

United States Patent [191 Viterbo et al.

[ 51 Sept. 23, 1975 DIBENZOCYCLOHEPTAN-DIOXOLAN DERIVATIVES AND THEIR PREPARATION METHOD [75] Inventors: Rene Viterbo, Paris, France;

Giovanni Brancaccio; Giulio Cesare Perri, both of Naples, Italy [73] Assignee: Richardson-Merrell S.p.A., Naples,

Italy [22] Filed: Apr. 9, 1974 [21] Appl. No.: 459,272

[52] US. Cl. 260/247.7 E; 260/268 PC; 260/293.58; 260/326.5 CA; 424/248;

[51] Int. Cl. C07D 295/00 Primary Examiner-Robert Gerstl Assistant Examiner-Richard D. Kelly Attorney, Agent, or FirmGe0rge W. Rauchfuss, Jr.; Eugene O. Retter [57] ABSTRACT The invention relates to dibenzo-cycloheptan-dioxolan derivatives having antispastic activity and the method of preparing them.

6 Claims, N0 Drawings DIBENZOCYCLOHEPTAN-DIOXOLAN DERIVATIVES AND THEIR PREPARATION METHOD FIELD OF INVENTION 5 mentioned, for example, salts of acetic acid, lactic acid, This invention relates to pharmacologically active pyruvic acid, malonic acid, succinic acid, fumaric acid, cis-and/Or trans y l 3lmalic acid, tartaric acid, citric acid, ascorbic acid, macyclohepta-[ l ,2-d]-l ,3-dioxolanes and the methods of l i cid, b i id h l i id 4- preparing same. These compounds are represented by aminobenzoic acid, salicylic acid, phosphosalicylic the following general formula: 10 id, nd th lik These new compounds, upon undergoing pharmacological tests, showed pharmacological activities; partic- T ularly antispastic activity. These novel active com- CH-(CHmR pounds may be used in therapy alone or together with Z other active ingredients and may be administered at the i suitable doses in coated-tablets, tablets, capsules, suppositories, suspensions and solutions. Dosages can be adjusted to individual requirements. In Table ll there are exemplary results of some of the pharmacological tests according to the well known test methods. In our co-pending United States application Ser. No. 22 l .048, filed on Jan. 26, 1972, cisand transderivatives of 3a,- wherein R and R are each hydrogen and R is selected l2b-dihydro8H-dibenzo-[3,4:6,7]cyclohepta[ l,2-d]- from pyrrolidine, piperidine, morpholine, piperazine l,3-dioxolan-8-one and of 3a,] 2b-dihydro-8H-dibenzoand N"(lower)-alkyl piperazine and n is a whole inte' 25 [3,4:6,7]cyclohepta[ l,2-d]-1,3-dioxolan-8-ol are disger of O to 3, preferably 1. closed, which differ from these because of the missing DETAILS OF INVENTION llieagzggceland alcoholic function in 8 position of cyclo In the R definition (lower) alkyl means a chain of l The compounds of this invention are prepared startto 6 carbon atoms, that is, alkyl may be methyl, ethyl, ing fr m 10,1 l-dibr0m0-l0,l l-dihydro-5H-dibenpropyl, butyl, pentyl, hexyl, in linear or branched chains.

Among the inorganic acids which can be used we mention, for example, hydrochloric acid, hydrobromic acid, hydriodic acid, sulphuric, acid, phosphoric acid, and the like. Among the organic acids there may be zo[a,d]cycloheptane according to the following reaction scheme:

cis and/or trans cis and/or trans The compounds of this invention form stable addi- By reacting the dibromo compound II (Treibs W. et tionsalts with non-toxic. organic or inorganic acids. al.: Ber. 84, 67l (1951 with silver acetate in the pres- These pharmaceutically acceptable salts are also inence of aqueous acetic acid and saponifying the reaccluded within the scope of the present invention. tion product with methanolic KOH, we obtain cisl0,l l-dihydroxy-l0,l l dihydro-SH-dibenzo[a,d]cycloheptane. (lll) i I Y I By reacting the dibromo compound with silver ace mm in the presence of anhydrous acetic acid and saponifying the reaction product with alkaline hydroxide, j we obtain the trans isomer of dibenzocycloheptane as described by Rigaudy J. et al. (Bull. Soc. Chim. France 400, 1960). The compounds having'formula IV in their .cis or trans form are obtained according to the methods described by Buchanan G. L. and Jahvery D. B. (.I.O.C.

26, 4295, 1965) and by Rigaudy J. and Nedelec L.

(Bull. Soc. Chim. France 400, 1960). vBy reacting the diol compound with the prope haloketones or haloaldehydes or with their haloacetals one obtains Z-haloalkyldioxolans having formula W. (cisand/or trans-). The reaction takes place with or without solvent and in the presence or absence of a suitableacidic catalyst.

' According to the invention one can use aprotic solvents stable in reaction conditions, such as, for example, benzene, toluene, xylene, ethyl ether or petroleum ether; The reaction may be conducted at a temperature of between room temperature and'the boiling temperature of the solvent when the reaction is performed in the presence of asolvent, otherwise a reaction temperature of between 50 and 180C. is employed when-the reaction is performed in absence of solvent. The reaction time will depend on the temperature and is generally between about 60 minutes and l08 hours. The acid catalystmay be chosen from among Lewis acids,

ptoluensulphonic acid, sulphuric acid, hydrochloric acid or'phosphoric acid.

Upon completion the reaction mixture is cooled to room temperature, dried and the residue is purified by crystallization or distillation, or used as such in the further reactions.

By reacting cisand/or transcompounds of formula IV with a primary or secondary amine, HR according to the R definition, one obtains cisand/or trans-compounds of formula I. The reaction is performed by dis.- solving the 'haloderivative of formula lll (cis and/or trans) and the corresponding amine in a solvent stable 9 in reaction conditions. Generally in the invention toluene is preferred, but also benzene, xylene, ethyl ether, tetrahydrofuran, ethyl alcohol, methyl alcohol, petroleum ether and the like may be used.

To remove the hydrochloric acid split off during the reaction, twice as much amine involved in the reaction is used or a tertiary amine such as trimethylamine, tri ethylamine or dimethylaniline. or sodium or potassium carbonate or bicarbonate may also be employed.

This reaction is performed at a temperature varying from the room temperature to the boiling temperature of the solvent used, and the reaction time will depend on the temperature. By cooling the reaction mixture to room temperature one obtains a solid precipitate which t aforesaid ones.

PREPARATION A A suspension of 130 g of 'l0',ll-dibromo-l0,lldihydro-SH-dibenzo[a,d ]cyclohepteneand '195 g of silver acetate in 3000 m] of acetic acid and l90 ml of water is heated at 80 C. for.4 hours withstirring. The

reaction mixture is cooled then filtered to "remove the formed silver salt. The filtered solution is concentrated to dryness at a lowered pressure. The residue is added to l ,00 0. ml of an ethanolic solution of KOH at 10 percent. The. resulting 'solution is heated at about 100C. for l0 minutes. The mixture is cooled to room temperature, diluted with an equal volume of water,acidifie d with 4N HCl and the n 'extracted'several times with ethyl ether. The collected ethereal extracts are dehydrated andaconcentrated at a lowered pressure. The solid residue washed with benzene andthen with petroleum ether. 44 g (53%) of'the chromatographically pure cis-l0,l l-dihydroxy-l0,l-l-dihydro-5H-diben; zo[a,d]cycloheptene are obtained. M.P. l63l6.5 C. It is crystallized from EtOH. M.P. l73l75C'.

Calculated for C H O 79.62 /(C; 6.24%H. Found: 7 9.74"/?C; 6.52'71H. spectra in ethanol 95: max; 26l mu; 6 =490.

PREPARATION B I Aimi'xt-ure of 44 g of cis-l(),ll-dihydroxy-l0,lldihydro-5H-dibenzo[a,dlcycloheptene and 40 ml'of diethylacetal of alpha-bromoaldehyde is heated at l65l 70C. for 70-80 minutes. The cxcedent acetal is I removed at lowered pressure and the reaction mixture is treatedwith 20 ml of ethyl ether, left to settle at 0C.

is a hydrochloride of the base used to remove the hydrochloric acid. The precipitate is then filtered off and the filtered solution dried. The residue is purified by distillation, crystallization or chromatography. Accord ing to another method contemplated by the invention, the reaction mixture may be diluted with a water nonmiscible solvent such as benzene, toluene or ethyl ether; washed with water. dried over M1 80, and con centrated. The residueis purified 'by distillation, crysv for several hours and the formed solid is then collected by filtration. It is washed with 20 ml of cold ethanol and then with petroleum ether. 22 g of cis-3a,l Zb-dihydro- 2-(bromomethyl)-8H- dibenzo[3,4:6,7]cyclohepta[ l ,2-d]l ,3-dioxolan are obtained. M.P. ll72C.

Calculatedfor C H, BrO 61 .65%C; 4.57%H.

EXAMPLE 1 A mixture of 18 g (0.0543 mole) of cis-3a,l2bdihydro-2-(bromomethyl)-8H- dibenzo[3,4:6,7]cyclohepta[l,2-d]-l,3-dioxolan and 10 ml (0.] 13 mole) of morpholine in ml of toluene is heated to boiling for 70 hours. The reaction mixture is cooled then stirred with water to neutral pH. The organic phase is dehydrated over Na SO. and concentrated at a lowered pressure to dryness. The residue is added. to acetone and then filtered. l 1.6 g of cis- 3a,l 2b-dihydro-2-( morpholinomethyl )-8H-dibenzo- [3,4:6,7 ]cyclohepta[ l .2-d]-l ,3-di0xolan are obtained. M.P. l76-l78C.

Calculated for C H NO 74.75%C; 6.87%H; 4.15%N. Found: 74.53%C; 7.01%H; 4.40%N.

EXAMPLE 2 A mixture of 14 g (0.042 mole) of cis-3a,l2bdihydro-Z-(bromomethyl)-8H- dibenzo[ 3,4:6,7]cyclohepta[ l ,2-d]l ,3-dioxolan and 11 ml (0.11 mole) of piperidine in 150 ml of toluene is heated to boiling for 60 hours. The cooled reaction mixture is filtered to remove the formed solid compound. The filtered solution is stirred water to neutral pH, dehydrated over l la SO and then concentrated at a lowered pressure. The residue is treated with 1N HCl and the solid formed is collected by filtration. It is washed with water, EtOH and Et O. 5.6 g of cis-3a, 1 2bdihydro-2-(piperidinomethyl)-8H-dibenzo [3,4:6.7]cyclohepta[l,2-d]-l,3-dioxolan are obtained. M.P. 240242C. It is crystallized from EtOH. M.P. 24l242C.

Calculated for C H ClNO 71.05%C; 7.05%H; 3.77 /1N; 9.54%Cl. Found: 71.137rC; 7.l3 /(H; 3.73%N; 9.70%Cl.

EXAMPLE 3 A mixture of 9.5 g (0.028 mole) of cis-3a.l2bdihydro-Z-(bromomethyl)-8H- dibenzo[ 3.4:6.7]cyclohepta[ l ,2-d]-l ,3-dioxolan and 10 ml (0.119 mole) of pyrrolidine in 100 ml of toluene is heated to boiling for 60 hours. The reaction mixture is cooled and filtered to remove the solid compound. The filtered solution is stirred with water to neutral pH. dehydrated over Na SO and concentrated at a lowered pressure. The residue is treated with 60 ml of 2N HCl. The solid compound formed is filtered and crystallized from EtOH. 4.95 g of cis-3a.l2b-dihydro-2- (pyrrolidinomethyl)-8H-dibenzo[3.416.71cycloheptal,2-d]-1.3-dioxolan hydrochloride are obtained. M.P. 2l2-2 l4C.

EXAMPLE 4 A mixture of 7.94 g (0.024 mole) of cis-3a,l2B dihydro'2-(bromomethyl)-8H dibenzo[3,4:6,7]cyclohepta[ l.2 -d]-1.3-dioxolan and 4.8 g (0.048 mole) of N-methylpiperazine in 80 ml of toluene is heated to boiling for 60 hours. The reaction mixture is cooled, stirred with water. then dehydrated over Na SO and finally concentrated at a lowered pressure to complete removal of the solvent. The oily residue is dissolved in ethyl ether. The ethereal solution is mixed with ml of a solution of HCl in ethanol (1.8N). The precipitate formed is filtered and washed with ethanol, acetone and ethyl ether. 6.4 g of cis- 3a,l2b-dihydro-2-[(4-methyl-1-piperazinyl)methyl]- 8H-dibenzo[3,4:6,7]cyclohepta[ l ,2-d]-l ,3-dioxolan hydrochloride are obtained. M.P. 254257C. It is recrystallized. M.P. 266268C. with decomposition.

Calculated for C H N O 2HCl: 62.41%C;

6.67%H; 6.62%N; 16.75%Cl. Found: 62.24%C; 6.72%H; 6.47%N.

TABLE I l: R CH-(CH zfiks R R H Compound n R; isomcr Preparation B 1 Br cis Example I I Q B cis Example 2 l N cis h Example 3 l N cis Example 4 l N NCH;i cis Table ll Pharmacological activities (an) acute toxicity LD with fiducial limits (FL) (P=0.05)-in the mouse per ()8 Example LD mg/Kg/os (FL) I 2000 Z 2000 3 ll30(93llbl1l 4 2000 Spcarman-Karhcr (Finncy. D.J.-Statistical method in biological assay-2nd edition page 524 -(irifl'in and Company 1964) (h) antispastic activity Organ isolated "in vitro: guinea-pig ileum Stimulation hy BaCl: (5.l0""l and a pharmaceutically-acceptable-acid addition salt dibenzo[3,4:6,7]cyclohepta[l.2-d]-l.3-dioxolane or a e wherein f R2 are each y og 3 pharmaceutically acceptable acid addition salt thereof. lected from pyrrolidme, piperidine, morpholine, piper- A compound f Claim 1 which i 3 -3 21 azine, and N'-(lower)-alkyl pipcrazine; n is selected dihydm 2 (morphofinomethyl) 8H g S h l 5 dibenzo[3,4:6;7}cyclohepta[l,2-d]-l,3-dioxolan or a compoun decor mg tocdlm. "l pharmaceutically acceptable acid addition salt thereof. 3. A compound of claim 1 which IS cis-3a,l2b- 6 compound of claim which is cis 3a 12!} pharmaceutically acceptable acid addition salt thereof. l l y P 4, A compound f claim .1. which isl cis-,3a,l2bpharmaceutically acceptable acid addition salt thereof. dihydro-2-(piperidinomethyl)-8H 

1. A COMPOUND SELECTED FROM A 3A, 12B-DIHYDRO-8H-DIBENZO- 3,4:6,7
 2. A compound according to claim 1 in which n is
 1. 3. A compound of claim 1 which is cis-3a,12b-dihydro-2-(pyrrolidinomethyl)-8H-dibenzo(3,4:6,7)cyclohepta(1,2 -d)-1,3-dioxolane or a pharmaceutically acceptable acid addition salt thereof.
 4. A compound of claim 1 which is cis-3a,12b-dihydro-2-(piperidinomethyl)-8H-dibenzo(3,4:6,7)cyclohepta(1,2-d)-1,3-dioxolane or a pharmaceutically acceptable acid addition salt thereof.
 5. A compound of claim 1 which is cis-3a,12b-dihydro-2-(morpholinomethyl)-8H-dibenzo(3,4:6,7)cyclohepta(1,2-d)-1,3-dioxolan or a pharmaceutically acceptable acid addition salt thereof.
 6. A compound of claim 1 which is cis-3a,12b-dihydro-2-((4-methyl-1-piperazinyl)methyl)-8H -dibenzo(3,4:6,7)cyclohepta(1,2-d)-1,3-dioxolane or a pharmaceutically acceptable acid addition salt thereof. 